Management Team

Lawrence Blatt, Ph.D., MBA
Chief Executive Officer
  • Global Infectious Diseases Therapeutic Area Head – Janssen
  • Co-Founder, Chief Executive Officer – Alios BioPharma
  • Chief Scientific Officer – InterMune
  • Senior Vice President, Research – Ribozyme/SIRNA
  • Senior Director, Interferon Research – Amgen
Leo Beigelman, Ph.D.
  • Global Head Discovery Infectious Diseases – Janssen
  • Co-Founder, CSO – Alios BioPharma
  • Vice President, Chemistry – Ribozyme/SIRNA, InterMune
Julian Symons, D.Phil.
Executive Vice President
Chief Scientific Officer
  • Vice President, Disease Area R&D Leader, Respiratory Infections – Janssen
  • Senior Director, Product Development – Alios BioPharma
  • Virology Director – Roche
Lucinda Quan, JD
Executive Vice President
Chief Business Officer & General Counsel
  • Executive Director, Head Transactionalist, West Coast Hub for Business Development & Licensing – Merck
  • Vice President, Head of Legal Affairs – Alios BioPharma
  • Vice President, Legal Affairs & Associate General Counsel – InterMune
Sushmita Chanda, Ph.D., DABT
Executive Vice President
Preclinical Development
  • Vice President, Global Head of Preclinical Development, Infectious Diseases – Janssen
  • Vice President, Head of Preclinical Development – Alios BioPharma
  • Senior Director, Nonclinical Safety – Roche
John Fry
Executive Vice President
Clinical Development
  • Vice President, Global Head of Early Development, Infectious Diseases – Janssen
  • Vice President, Head of Clinical Development – Alios BioPharma
  • Director, Clinical Research, Gilead Sciences
Matthew W. McClure, MD
Executive Vice President
Chief Medical Officer
  • Chief Medical Officer – Second Genome
  • Senior Director, Clinical Research – Janssen/Alios Biopharma
  • Senior Director, Clinical Research – Portola Pharmaceuticals
Lesley Ann Calhoun
Executive Vice President
Chief Financial Officer
  • SVP, Finance & Administration, Chief Accounting Officer – Global Blood Therapeutics
  • Vice President, Finance – Hyperion Therapeutics
  • Senior Director of Finance, Corporate Controller – Theravance
  • Senior Director of Finance and Corporate Controller – Cell Genesys
David B. Smith, Ph.D.
Vice President
Head of Chemical Operations
  • Vice President, Global Disease Area R&D Leader, Hepatology – Janssen
  • Senior Director, Product Development – Alios BioPharma
  • Principal Research Scientist – Roche
Pierre Raboisson, Pharmacist D., Ph.D
Vice President
Head of Small Molecule Medicinal Chemistry
Head of Belgium Site (Leuven)
  • Vice President, Global Head of Medicinal Chemistry – Infectious Disease – Janssen
  • Vice President, Head of Infectious Diseases Discovery EU – Janssen
  • Vice President, Head of Medicinal Chemistry Europe – Janssen

Board of Directors

Jack B. Nielsen

Jack B. Nielsen has served as Chairman of the board of directors of Aligos since August 2018. Jack has been a Managing Director at Vivo Capital LLC, since 2017. From 2001 to February 2017, Jack worked within the Novo A/S organization and its venture activities in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. From 2006 to 2012, Jack was employed as a Partner at Novo Ventures (US) Inc. in San Francisco. Jack currently serves on the Board of Directors of Crinetics Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Harmony Biosciences, Inc, and Maculogix, Inc. He previously served on the board of directors of the following public companies: Merus, N.V., Apollo Endosurgery, and Akebia Therapeutics. Jack received a M.Sc. in Chemical Engineering from the Technical University of Denmark, and a Masters in Management of Technology from Center for Technology, Economics and Management, Technical University of Denmark

Lawrence Blatt

Lawrence Blatt, Ph.D., MBA, co-founded Aligos and has served as the Chief Executive Officer and a member of the board of directors since March 2018. Dr Blatt has more than 29 years of drug research and development experience with a specific focus on biology of the immune system, infectious diseases, antiviral therapies, and relevant therapeutic interventions. Prior to Aligos, he was the Global Head of Infectious Diseases and Vaccines at Johnson & Johnson. Dr. Blatt is a serial biotech entrepreneur who co-founded Alios BioPharma and served as its Chief Executive Officer, President and Director from inception to acquisition by Johnson & Johnson in 2014, developing therapies for viral diseases, including respiratory syncytial virus (RSV) and hepatitis C. Prior to Alios, he was Chief Scientific Officer of InterMune, Inc. (acquired by Roche in 2014). Dr. Blatt also held successive positions as Vice President of Research of SiRNA/Ribozyme Therapeutics, Vice President of Product Development at National Genetics Institute, and Product Development Team Leader, Interferons at Amgen. Lawrence achieved a Doctorate in public health administration from the University of La Verne and completed his MBA from California State University, Northridge and a Bachelor of Science degree in Microbiology from Indiana University. He is also a co-founder and chairman of the Board of Directors for Alveo Diagnostics, Alameda, California. Dr. Blatt is the recipient of the Ernst & Young Entrepreneur of the Year Award in the life science category and has co-authored over 100 peer reviewed scientific publications as is listed as a co-inventor on several issued and pending patent applications relating to treatment of viral diseases.

Leonid Beigelman

Leonid Beigelman, Ph.D., co-founded Aligos and has served as the President and a member of the board of directors since March 2018. Leo has over 30 years of experience in medicinal chemistry and drug discovery with internationally recognized expertise in nucleic acids chemistry. Prior to Aligos, he was VP, Medicinal Chemistry and Global Head of Discovery of Janssen IDV (a pharmaceutical company of Johnson & Johnson) as well as Head of COE in Nucleic Acids building diverse discovery portfolio in RSV, influenza, HCV and HBV. Prior to that, Leo co-founded Alios BioPharma (2008) and served as its Chief Scientific Officer until it was acquired by Johnson & Johnson in 2014. From 2005 to 2009, Leo served as Vice President of Medicinal Chemistry and Technical Operations at InterMune, Inc. leading several teams in HCV drug discovery and CMC activities. From 2002 to 2005, Leo worked at Transgenomic, Inc. as Vice President of Nucleic Acids Chemistry, where he helped to establish a large-scale facility for GMP manufacturing of oligonucleotides and building blocks for oligonucleotide synthesis. While at Ribozyme Pharmaceuticals from 1992-2002 (which became SiRNA), Leo assumed positions of increasing responsibility culminating in appointment as Senior Director of Chemistry and Biochemistry. He initiated and led transition from ribozyme to siRNA technology that resulted in Merck’s acquisition of SiRNA. In 1991, Leo joined United States Biochemical as a research scientist and participated in the formation of Ribozyme Pharmaceuticals Inc. Leo received his Ph.D. in Bioorganic Chemistry from The Institute of Molecular Biology (USSR Academy of Sciences) and completed his postdoctoral training at the Department of Pharmacology, Yale University Medical School. He has co-authored more than 100 publications and is a named co-inventor on more than 200 patents.

K. Peter Hirth

Peter Hirth, Ph.D. has served as a member of the board of directors of Aligos since August 2018. He has more than 30 years of drug discovery and development expertise. Most recently, Peter served aas co-founder and CEO of Plexxikon, Inc., where he built a novel, structure-guided drug discovery platform, which has brought several new chemical entities (NCEs) into the clinic such as Zelboraf®, which was approved by the FDA for metastatic melanoma together with a companion diagnostic. Before that, Peter was with Sugen Inc., where he was instrumental in building the company from its inception, advancing several kinase inhibitors through clinical trials in oncology. Prior to Sugen, Peter was a Vice President of Research at Boehringer Mannheim where he successfully led the company’s erythropoietin program to approval. Earlier in his career, Peter was a research scientist with the Max Planck Institute, following the completion of his post-doctoral work at the University of California, San Diego. Peter currently serves as the chairman of IO Bio in Copenhagen and as a director on the BOD of Iconic Therapeutics in South San Francisco, CA, SutroVax Inc. in South San Francisco and Trex Bio in South San Francisco. Former BOD memberships include Afferent Pharmaceuticals in San Mateo, CA and Kolltan Pharmaceuticals in New Haven, CT and Alios Biopharma in South San Francisco. He received his Ph.D. in molecular genetics from Heidelberg University, Germany.

Peter Moldt

Peter Moldt has served as a member of the board of directors of Aligos since August 2018.  Peter joined Novo Ventures (US) Inc. in San Francisco, California in 2012. From 2009-2012, Peter was employed with Novo A/S as a partner in Novo Ventures in Denmark. In 2004, Peter co-founded Curalogic A/S, served as CEO until 2009 and took the company public in 2006. From 2000-2004, he was Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development. He is currently a member of the Board of Directors of Bolt Therapeutics (executive chairman), E-Scape Bio., Outpost  and Viewpoint. Peter holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy. He has also been a post doc with Yale University’s department of organic chemistry.

Carole Nuechterlein

Carole Nuechterlein has served as a member of the board of directors of Aligos since August 2018.  She has led the Roche Venture Fund since 2002.  Prior to that, from 1998 to 2001, Carole served as General Counsel for SangStat, a public biotech company acquired by Genzyme.  Carole currently serves as a member of the boards of directors of Millendo (MLND) and a number of private companies, including Maculogix, Vivet, CiVi, Lumos, Mission, Arch Oncology, Second Genome and Lysosomal Therapeutics Inc. She also served as a member of the board of directors of AveXis (AVXS) prior to its acquisition by Novartis.  Carole received a B.A. from Valparaiso University and a J.D. from University of Michigan.

Thomas Woiwode

Thomas Woiwode, Ph.D. has served as a member of the board of directors of Aligos since August 2018. Tom has been with Versant Venture Management, LLC, or Versant Ventures, a healthcare investment firm, since 2002 in various capacities, serving as a managing director since July 2014 and previously as a venture partner from June 2011 to July 2014. He has also served in a number of operating roles over this time, most recently as the chief operating officer of Okairos AG, or Okairos, a biopharmaceutical company developing genetic vaccines for major infectious diseases, from April 2011 until May 2013. Prior to Okairos, Tom co-founded EuroVentures, a wholly owned biotechnology incubator within Versant Ventures, and in this role, served as the founding chief business officer for three biotechnology companies created within Versant Ventures. Before joining Versant Ventures, Tom also served as a research scientist at XenoPort, Inc. Tom currently serves on the board of directors of Gritstone, CRISPR Therapeutics AG and Adverum Biotechnologies, Inc., and served on the board of directors of Audentes Therapeutics, Inc. from July 2013 to July 2017. Tom also serves on the board of directors of several private companies. Tom holds a B.A. in English and a B.S. in Chemistry from the University of California, Berkeley and a Ph.D. in Organic Chemistry as an NSF Fellow from Stanford University.

Kathy Glaub

Ms. Glaub joined the Aligos board of directors in October 2019. She brings more than 30 years of experience in corporate development and strategy, financing and company-building for innovative life science and technology companies. She is co-founder and executive chair of CuraSen Therapeutics, and serves on the boards of Escient Pharmaceuticals and IO Biotech. She has been a past director of Codexis, Inc. and Afferent Pharmaceuticals. Following Ms. Glaub’s appointment to the board of Afferent Pharmaceuticals in 2013, she was appointed chief executive officer in 2014. Ms. Glaub led the company’s advancement of AF-219/MK7264 (gefapixant) to Phase 3 readiness for the treatment of chronic cough, raised $80 million in additional private funding, and led the 2016 sale of the company to Merck for $1.25 billion. Previously, Ms. Glaub served as president of Plexxikon for 12 years, where she led the company’s business and financing strategies, negotiated several multimillion-dollar partnerships, and led the sale of the company to Daiichi Sankyo for nearly $1 billion in 2011. She also was instrumental in Plexxikon’s advancement of multiple novel molecules to the clinic, including advancement of Zelboraf®, a targeted treatment for melanoma, along with its companion diagnostic to market approval in 2011. She also previously held positions as senior vice president and chief financial officer of Cell Genesys, treasurer of Genentech, and various finance and treasury roles with Intel Corporation. Ms. Glaub received her BA from the University of California, Berkeley, and her MBA from Northwestern University.

Qingqing Yi

Qingqing Yi has served as a member of the board of directors of Aligos since December 2019. He is currently a Partner at Hillhouse Capital Group and has worked with Hillhouse since its inception in 2005. Mr. Yi leads Hillhouse’s healthcare investments and is currently a director of BeiGene, Ltd. Prior to joining Hillhouse, Mr. Yi was an Equity Research Analyst at China International Capital Corporation. He received a B.S in Engineering from Shanghai Maritime University, as well as an M.B.A. from University of Southern California. Mr.Yi’s extensive experience in investing in the healthcare sector contributed to our board of directors’ conclusion that he should serve as a director of our company.